Lentiviral Haemopoietic Stem/Progenitor Cell Gene Therapy for Treatment of Wiskott-Aldrich Syndrome: Interim Results of a Non-Randomised, Open-Label, Phase 1/2 Clinical Study

The Lancet Haematology - United Kingdom
doi 10.1016/s2352-3026(19)30021-3
Full Text
Abstract

Available in full text

Categories
Hematology
Date
Authors
Publisher

Elsevier BV

Related search

Lentiviral Hematopoietic Stem Cell Gene Therapy in Patients With Wiskott-Aldrich Syndrome

Pediatrics
Child HealthPediatricsPerinatology
2014English

Wiskott-Aldrich Syndrome

English

458. Gene Expression and T Cell Receptor Repertoire Analyses in Gammaretroviral Gene Therapy of Wiskott-Aldrich-Syndrome

Molecular Therapy
Molecular MedicineMolecular BiologyPharmacologyMedicineGeneticsDrug Discovery
2014English

Wiskott-Aldrich Syndrome

2020English

High-Dose Immunoglobulin Therapy of Wiskott-Aldrich Syndrome

Pediatric Hematology and Oncology
Child HealthOncologyPediatricsPerinatologyHematology
1987English

166. Lentiviral Hematopoietic Stem Cell Gene Therapy for Sjögren-Larsson Syndrome

Molecular Therapy
Molecular MedicineMolecular BiologyPharmacologyMedicineGeneticsDrug Discovery
2016English

Sandoz Rituximab for Treatment of Diffuse Large B-Cell Lymphoma: Interim Safety Results of the Non-Interventional, Observational, Multicenter, Open-Label Reflect Study

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Hematopoietic Cell Transplantation for Wiskott-Aldrich Syndrome: Advances in Biology and Future Directions for Treatment

Immunology and Allergy Clinics of North America
AllergyImmunology
2010English

Wiskott-Aldrich Syndrome Protein Is Required for Regulatory T Cell Homeostasis

Journal of Clinical Investigation
Medicine
2007English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy